Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
Diabetes Care2007Vol. 31(1), pp. 20–25
Citations Over TimeTop 10% of 2007 papers
Abstract
Although noninferiority of PPT to BBT was not demonstrated, findings for A1C reduction, percentage of patients achieving A1C targets, hypoglycemia, and number of required injections should be considered in the individual decision-making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes.
Related Papers
- A Pilot Study of the Use of Insulin Glargine in Combination with Short Acting Insulin Analogue in Adolescents with Type I Diabetes Mellitus in Hong Kong(2004)
- Improvement in overall blood glucose control with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with Type 1 diabetes.(2003)
- Study on the Efficacy of Glargine in the Treatment of Diabetes(2007)
- → Comparison of the efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with diabetes(2015)